Biodesix, Inc. (BDSX)

Market Cap	51.64M
Revenue (ttm)	76.56M
Net Income (ttm)	-41.08M
Shares Out	7.80M
EPS (ttm)	-5.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	77,039
Open	6.71
Previous Close	6.42
Day's Range	6.34 - 6.75
52-Week Range	3.44 - 34.40
Beta	0.98
Analysts	Strong Buy
Price Target	32.50 (+390.94%)
Earnings Date	Nov 3, 2025

About BDSX

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 28, 2020
• Employees: 273
• Stock Exchange: NASDAQ
• Ticker Symbol: BDSX
• Website: https://www.biodesix.com

Financial Performance

In 2024, Biodesix's revenue was $71.32 million, an increase of 45.30% compared to the previous year's $49.09 million. Losses were -$42.93 million, -17.67% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for BDSX stock is "Strong Buy." The 12-month stock price target is $32.5, which is an increase of 390.94% from the latest price.

Price Target

$32.5

(390.94% upside)

Analyst Consensus: Strong Buy